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Summary. Background: The aim of the current study was to
perform two separate meta-analyses of available studies
comparing low-molecular-weight heparins (LMWHs) vs.
unfractionated heparin (UFH) in ST-elevation myocardial
infarction (STEMI) patients treated (i) with primary percuta-
neous coronary intervention (pPCI) or (ii) with PCI after
thrombolysis. Methods: All-cause mortality was the pre-
specified primary endpoint and major bleeding complications
were recorded as the secondary endpoints. Relative risk (RR)
with a 95%confidence interval (CI) and absolute risk reduction
(ARR) were chosen as the effect measure. Results: Ten studies
comprising 16 286 patients were included. The median follow-
up was 2 months for the primary endpoint. Among LMWHs,
enoxaparin was the compound most frequently used. In the
pPCI group, LMWHs were associated with a reduction in
mortality [RR (95% CI) = 0.51 (0.41–0.64), P < 0.001,
ARR = 3%] and major bleeding [RR (95% CI) = 0.68
(0.49–0.94), P = 0.02, ARR = 2.0%] as compared with
UFH. Conversely, no clear evidence of benefits with LWMHs
was observed in the PCI group after thrombolysis. Meta-
regression showed that patients with a higher baseline risk had
greater benefits from LMWHs (r = 0.72, P = 0.02). Conclu-
sions: LMWHs were associated with greater efficacy and safety
than UFH in STEMI patients treated with pPCI, with a
significant relationship between risk profile and clinical benefits.
Based on this meta-analysis, LMWHs may be considered as a
preferred anticoagulant among STEMI patients undergoing
pPCI.
Keywords: low-molecular-weight heparin, percutaneous coro-
nary intervention, ST-elevation myocardial infarction, unfrac-
tionated heparin.
Introduction
Unfractionated heparin (UFH) is regarded as standard anti-
coagulant therapy for the treatment of ST-elevation myocar-
dial infarction (STEMI) patients, including those treated with
percutaneous coronary intervention (PCI). Guidelines from the
American College of Cardiology and European Society of
Cardiology recommend the use of UFH with a level of
evidence C [1,2]. However, this recommendation is not based
on comparison data with a placebo, but only on the strong
belief that anticoagulation therapy is required during the
procedure. There is evidence of efficacy for the low-molecular-
weight heparins (LMWHs) in STEMI patients treated with
fibrinolytics [3], but their use in STEMI patients treated with
PCI has been controversial because of the scant available data
up to a few years ago.
More recently, several observational studies, analyses of
large randomized trials (RCTs) or ad hoc RCTs have
compared LMWHs with UFH in STEMI populations treated
with primary PCI (pPCI) or PCI performed after thrombolysis.
The aims of this investigation were: (i) to perform two
separate meta-analyzes of available studies comparing
Correspondence: Eliano Pio Navarese, Department of Cardiology and
Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus
Copernicus University, Skodowskiej-Curie Street No 9, 85-094
Bydgoszcz, Poland.
Tel.: +48 52 585 40 23; fax: +48 52 585 40 24.
E-mail: eliano.navarese@alice.it
Received 20 April 2011, accepted 11 July 2011
Journal of Thrombosis and Haemostasis, 9: 1902–1915 DOI: 10.1111/j.1538-7836.2011.04445.x
 2011 International Society on Thrombosis and Haemostasis
LMWHs vs. UFH in STEMI patients treated with either pPCI
or PCI after thrombolysis; and (ii) to assess whether the effects
of different anticoagulation regimens on mortality may be
related to the patients baseline risk profile.
Methods
The present meta-analysis was performed according to estab-
lished methods, according to the guidelines of the Cochrane
Collaboration [4], the guidelines of the MOOSE group [5] and
the updated guidelines on systematic reviews of non-random-
ized studies [6].
Search strategy
A systematic investigation was performed of all the published
and unpublished literature, including oral presentations, to
minimize the risk of bias. A search covering the period from
January 1993 to March 2011 was conducted by two
independent investigators using MEDLINE, CENTRAL
and Google Scholar databases. Proceedings from the Scien-
tific Sessions of the American College of Cardiology [http://
www.acc.org], American Heart Association [http://www.a-
ha.org], European Society of Cardiology [http://www.escar-
dio.org], Transcatheter Cardiovascular Therapeutics [http://
www.tctmd.com] and EuroPCR [http://www.europcr.com]
were also considered. The following keywords were applied:
low-molecular-weight-heparins, unfractionated heparin,
angioplasty and ST-elevation myocardial infarction. Refer-
ences of retrieved studies were searched manually for
additional trials. Efforts to contact authors were performed
to obtain further details or additional references. No
language restrictions were applied.
Study endpoints
All-cause mortality was the primary pre-specified endpoint;
major bleeding complications were recorded as a secondary
endpoint. Mortality was evaluated at long-term follow-up, if
available; otherwise, in-hospital or 30-day data were included.
Data on major bleeding (at 30 days if available, otherwise at
shorter follow-up) were managed according to the TIMI
criteria, when available; if not, by study protocol definition.
Selection criteria and internal validity
RCTs and non-randomized studies were selected based on the
following inclusion criteria: studies comparing LMWHs vs.
UFH in STEMI patients treated either with pPCI or with
thrombolysis followed by PCI. Main exclusion criteria were: (i)
comparison between LMWHs and UFH in patients with
NSTEMI [29–34], with STEMI treated with thrombolysis only
[35–40] or undergoing elective PCI [25,27–28]; (ii) absence of
comparator treatment group (i.e. UFH) [41]; (iii) combined
data (pPCI and thrombolysis) with no separate data on pPCI
[42]; and (iv) duplicate reporting [43–44] (Fig. 1). The quality of
the included studies was appraised by two unblinded reviewers.
Non-randomized studies were evaluated using the validated
Newcastle–Ottawa Scale [4]. Data were abstracted on pre-
specified forms by two independent investigators, neither
involved in any of the retrieved studies; divergences were
resolved by discussion with a third investigator. Pre-specified
extracted data included: trial name/first author, publication
year, study design, study-inclusion and exclusion criteria, the
number of patients, dose of LMWH/UFH, type of LMWH
used, clinical outcome (mortality, major bleeding), major
bleeding definition, glycoprotein (Gp) IIb/IIIa inhibitor use,
Potentially relevant studies
identified and screened for
retrieval
n = 289
Studies retrieved for more 
detailed evaluation
n = 29
Potentially appropriate studies to
be included in the meta-analysis
n = 14 Studies excluded n = 4
Studies excluded n = 15
Studies excluded n = 260
Reasons: non relevant articles
Studies to be included in the
meta-analysis
n = 10 (n = 16 286)
Reasons :
Reasons:
1) Absence of comparator (UFH) (n =141)
1) UFH vs LMWH in elective PCI (n = 325, 27–28)
2) UFH vs LMWH in NSTEMI (n = 529–34)
3) UFH vs LMWH in STEMI treated with
    thrombolysis (n = 735–40)
2) Combined data primary PCI and PCI after
    thrombolysis (n = 142) 
3) Duplicate reporting (n = 243–44)
Fig. 1. Flow diagram of the reviewing process.
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female gender, anterior MI, the longest follow-up available for
mortality and major bleeding.
Comparative studies were classified into three categories
according to study design according to the Cochrane Inter-
vention Meta-analysis Handbook [4]: (1) non-randomized
controlled trials (NRCTs) (patients with STEMI treated with
pPCI/PCI after thrombolysis who were non-randomly
allocated to UFH or LMWH treatment); (2) retrospective
cohort studies (RCS) (patients with STEMI treated with
pPCI/PCI after thrombolysis who were retrospectively iden-
tified and in whom outcomes after LMWH or UFH
treatment were assessed; and (3) RCTs (patients with STEMI
treated with pPCI/PCI after thrombolysis who were ran-
domly allocated to LMWH or UFH treatment). Categories 1
and 2 were considered as non-randomized comparative
studies.
Statistical analysis
Relative risk (RR) and 95% confidence intervals (95% CI)
were used as summary statistics. Heterogeneity was assessed
using Cochrans Q test, with a two-tailed P = 0.1, as
conventionally recommended [7]. The statistical inconsistency
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d.f. is its degrees of freedom, was also employed to overcome
the low statistical power of Cochrans Q test [8].
Pre-specified analyses are presented separately for the pPCI
and PCI after thrombolysis groups. Separate pre-specified
analyses were also performed with or without the RCT and aP
for interaction was calculated to formally explore any statistical
difference between the two analyses.
To increase the accuracy of the meta-analysis, we reported
the analysis of both crude and adjusted estimates when
available from the retrieved studies, according to the Cochrane
Guidelines [4].
For the crude estimate computation, the pooled RR was
calculated using a Fixed-Effect model with the Mantel–
Haenszel method.
The adjusted estimates were pooled by the inverse variance
method using the log RR available from the retrieved studies;
in case of availability of the odds ratio (OR) only, we converted
this into the RR using the following equation according to the
Cochrane Guidelines [4]: RR = OR/1 – ACR · (1 ) OR),
where ACR is the assumed control risk. Adjusted hazard ratios
were accepted as RR.
In case of significant benefits from one or another strategy,
the absolute risk reduction (ARR) was also calculated.
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Potential publication bias for the subgroups was examined by
constructing a funnel plot, in which the standard error (SE) of
the ln RR was plotted against the RR (mortality or major
bleeding). In addition, a mathematical estimate of the asym-
metry of this plot was provided using a linear regression
approach [9]. TheDuval and Tweedie non-parametric trim and
fill method was used to obtain symmetry in the funnel plot and
to determine the impact of hypothetical negative or imputed
studies on the pooled estimate [10].
The following sensitivity analyses were also performed: (i)
the influence of each study was assessed by testing whether,
deleting each in turn, would have significantly changed the
pooled results of the meta-analyses (sensitivity analysis); and
(ii) separate pre-specified analyses were carried out for the
NRCT or RCS to test the potential influence on the results of
the non-randomized studies design.
The relationship between the effect on mortality of LMWHs
vs. UFH and the patients risk profile in each study (study level
variable) was evaluated using a Fixed-Effect meta-regression
analysis, regressing ARR against the control group event rate
as a proxy for the risk of mortality using the inverse variance of
the ARR as a weight [11]; the related number needed to treat
(NNT) as the inverse of the ARR for the different risk profiles
in the meta-regression was also computed.
Finally, survival and major bleeding after Gp IIb/IIIa
inhibitors as concomitant antithrombotic therapy with UFH
or LMWHs were evaluated using meta-regression, regressing
the rate of Gp IIb/IIIa inhibitor use against the log RR from
the included studies.
Review Manager 5.1 (The Nordic Cochrane Center,
Købehvn, Denmark), Stata/SE, version 10, for Windows
(StataCorp, Houston, TX, USA) and SPSS for Windows




Nine non-randomized studies [12–20] and one RCT [http://
spo.escardio.org/eslides/view.aspx?eevtid=40&fp=2042] were
included in the meta-analysis that involved a total of 16 286
patients:6622and9664allocatedtotheLMWHandUFHgroup,
respectively. Among LMWHs, enoxaparin was the compound
most frequently used. Table 1 lists the study characteristics. Six
non-randomized studies had a prospective design; three were
retrospective analyses. The majority of the included studies
reported until 1-month follow-up for mortality outcome,
whereas four studies reported a longer follow-up (range 3–
15 months); the median follow-up was 2 months. Concerning
major bleeding complications, data were mostly available up to
hospitaldischarge,whereastwostudiesreporteddataat30 days.
The FINESSE (Facilitated INtervention with Enhanced
reperfusion Speed to Stop Events) trial [16] reported separate
results for pPCI and PCI after thrombolysis, which were
computed separately in the meta-analysis as pre-specified. In
the CLARITY TIMI-28 (CLopidogrel as Adjunctive Reper-
fuIion TherapY – Thrombolysis in Myocardial Infarction 28)
trial [14] 50% of patients received a LMWH, with enoxaparin
administered to the majority of these (85%) and nadroparin,
dalteparin, tinzaparin or certoparin to the remaining 15%. PCI
exTRACT TIMI-25 (EnoXaparin and Thrombolysis Reper-
fusion for ACute myocardial infarction Treatment, Throm-
bolysis InMyocardial Infarction 25) [15] is a subgroup analysis
of a RCT, including patients who underwent PCI after
thrombolysis. It was considered as a non-randomized study,
in compliance with the Cochrane Guidelines for systematic
reviews and meta-analyzes [4].
Risk of bias of included studies
Table 2 summarizes quality ratings and risk of bias assessment
for the non-randomized studies. Overall, the quality of the
studies was good and high scores were achieved. Most of the
studies reported adjusted estimates for the primary endpoint
and when not available (two studies) the baseline clinical
characteristics were found to be well matched between the two
arms (LMWHsvs.UFH). In themajorityof the includedstudies
the accuracy of the data was checked by (i) an independent
Clinical Events Committee, (ii) using standardized case report
forms completed by a trained study coordinator [19], (iii) by
source documents for completeness and for internal consistency
[12] or (iv) by social security indices [20].
Primary endpoint
Mortality Nine studies (including 14 620 patients) reported
the mortality outcome in the group treated with LMWHs vs.
UFH (Fig. 2A). In the overall cohort of patients there were a
total of 694 deaths, 3.61% (211/5842) in the LMWHgroup and
5.50% (483/8778) in the UFH group. No heterogeneity or
statistical inconsistency was observed in the results.
LMWHs were associated with a marked reduction in
mortality in the pPCI group: RRfixed (95% CI) = 0.51
(0.41–0.64), P < 0.001, ARR = 3% (NNT = 33) (Fig. 2A,
upper panel), whereas no significant reduction in mortality was
found in STEMI patients undergoing PCI after thrombolysis:
RRfixed (95% CI) = 1.01 (0.78–1.32), P = 0.92 (Fig. 2A,
lower panel).
In the pPCI group, the pre-specifed meta-analysis of non-
randomized studies conducted excluding the only RCT
ATOLL (Acute STEMI Treated with primary angioplasty
and intravenous enoxaparin Or UFH to Lower ischemic
and bleeding events at short- and Long-term follow-up)
[http://spo.escardio.org/eslides/view.aspx?eevtid=40&fp=
2042] confirmed the benefits of LMWHs found in our
overall analysis and in the dataset coming from the
randomized study [RRfixed (95% CI) = 0.50 (0.40–0.63),
P < 0.001].
In the adjusted estimates analysis, the benefits of LMWHs
were strongly maintained in the pPCI group [RR (95%
CI) = 0.50 (0.39–0.63), P < 0.001], and they became signif-
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icant in favour of LMWHs in the PCI after the thrombolysis
group [RRfixed (95% CI) = 0.76 (0.64–0.90), P = 0.001]
(Fig. 2B).
In the pPCI group, stratified analyses of studies with 1-
month follow-up or longer follow-up (range 3–15 months)
were also performed and the results were found consistent
in favour of LMWH treatment: (i) 1-month follow-up
RRFixed (95% CI) = 0.43 (0.29–0.63), P < 0.001; (ii)
longer follow-up RRFixed (95% CI) = 0.56 (0.43–0.73),
P < 0.001.
The funnel plot for mortality for the pPCI group demon-
strated a slight asymmetry between the right- and left-hand
sides of the plot, however, the Eggers test was not significant
(P = 0.07). We therefore further explored any potential bias
using theDuval and Tweedie trim and fill method, whereby the
asymmetric studies from the left-hand side of the plot were
trimmed to locate the unbiased effect; the plot was then filled by
reinserting the trimmed studies on the left as well as their
imputed counterparts to the right of the mean effect, producing
a symmetric plot. The overall effect onmortality reported in the
forest plot appeared valid with trivial publication bias effect
because the observed estimates were similar to the adjusted
estimates (Fig. 3).
As shown in Fig. 4, using meta-regression, a significant
relationship between benefits in mortality reduction with
LMWHs compared with UFH and patients risk profile was
found (r = 0.72; P = 0.02); the greater the risk, the higher the
associated benefit from the administration of LMWHs. The
related NNT to prevent one death decreased in favour of
LMWHs at increasing risk profiles.
Major bleeding Ten studies, including 16 286 patients,
reported the rate of major bleeding complications. No
publication bias was found on the funnel plot. The overall
incidence of major bleeding was 1.73% (115 out of 6622
patients) in the LMWH group and 3.22% (312 out of 9664
patients) in the UFH group.
LMWH treatment was associated with a significant reduc-
tion in the rate of major bleeding complications in the pPCI
group: RRfixed (95% CI) = 0.68 (0.49–0.94), P = 0.02,
ARR = 2.0% (NNT = 50) (Fig. 5, upper panel). However,
no significant differences were observed between the two agents
in the PCI after thrombolysis group: RRfixed (95% CI) = 0.91
(0.66–1.25), P = 0.56 (Fig. 5, lower panel).
In the pPCI group, the results did not change after the
exclusion of the ATOLL study: RRfixed (95% CI) = 0.60
(0.42–0.85), P = 0.004.
Overall sensitivity analyses
Sensitivity analysis, performed by removing each of the studies
one at a time, demonstrated that no single study influenced the
overall results.
Test for interaction
The interaction test yielded v2 = 0.05, d.f. = 1, P = 0.82,
showing no significant difference between the results for
mortality in the pPCI group when obtained from the RCT
vs. non-randomized studies. The effects of the two non-
randomized study type categories were similar (NRCS vs.
RCS) with v2 = 2.61, d.f. = 1, P = 0.11. These concordant
results applied also to major bleeding outcomes for the pPCI
and the PCI after thrombolysis groups, suggesting that the
summary effect was robust and justified.
Discussion
The main finding of the meta-analysis is that the use of
LMWHs in patients undergoing pPCI for STEMI is associated
with a reduction in rates of mortality and major bleeding as
compared with the use of UFH.
LMWHs have several pharmacological properties that may
theoretically explain their greater efficacy. As compared with
UFH, LMWHs have a four-fold greater activity against
activated factor X that is crucial to promote the production of
thrombin. LMWHs also possess a much more predictable
anticoagulant response than UFH as they do not bind to
plasma proteins. Moreover, pleiotropic effects such as blunt-
ing the increase in von Willebrand factor and a relative lack of
associated platelet activation might influence its antithrom-
botic properties in addition to superior anticoagulant effects
[21–23]. Based on these pharmacokinetic and pharmacody-
namic characteristics, LMWHs provide a pharmacologic-
Table 2 The Newcastle Ottawa Scale for non-randomized studies assigns star for three area of study quality: selection, comparability and outcome. Each
criterion is worth one star, with the exception of comparability. In this area, a study can receive up two stars for two or more important factors
Non-randomized comparative studies Selection Comparability Outcome Score Adjusted estimates/Methods of adjustment
ASSENT-3 wwww ww www 9/9 Multivariate and propensity score analysis
Brieger et al. [13] wwww ww ww 8/9 Multivariate analysis
CLARITY TIMI-28 wwww ww www 9/9 Multivariate analysis
EXTRACT TIMI-25 wwww ww www 9/9 Multivariate analysis
FINESSE wwww ww www 9/9 Multivariate and propensity score analysis
Galeote et al. [17] wwww – ww 6/9 No adjusted estimates available*
Khoobiar et al. [18] wwww – ww 6/9 No adjusted estimates available*
Li et al. [19] wwww ww www 9/9 Multivariate and propensity score analysis
Zeymer et al. [20] wwww ww www 9/9 Propensity score analysis
*Adjustment method was probably unnecessary since baseline characteristics were well matched.
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profile that may be better suited for PCI in STEMI than
UFH.
Currently, increasing data suggest benefits associated with
LMWHs in elective patients [24] and acute patients under-
going PCI, as shown in the sub-analysis of the FINESSE
trial [16]. In FINESSE lower rates of death, MI, urgent
revascularization, or refractory ischemia through 30 days
were associated with LMWHs vs. UFH in patients treated
with primary or facilitated PCI (5.3% vs. 8.0%, respec-
tively), as well as lower all-cause mortality at 90 days in
patients treated with pPCI or facilitated PCI (3.8% vs.
5.6%, respectively). The incidence of non-intracranial TIMI
major bleeding was also lower with enoxaparin (2.6% vs.
4.4%).
A sub-analysis of the ExTRACT-TIMI-25 (EnoXaparin
and Thrombolysis Reperfusion for ACute myocardial infarc-
tion Treatment, Thrombolysis In Myocardial Infarction 25)
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Fig. 2. (A) Individual and summary relative risks (risk ratios) for mortality in patients treated with low-molecular-weight heparins (LMWHs) vs.
unfractionated heparin (UFH). (B) Individual and summary adjusted relative risks (risk ratios) for mortality in patients treated with LMWHs vs. UFH.
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UFH treatment group who underwent PCI [15]. It provides
one of the largest cohorts to date of STEMI patients receiving
thrombolysis and anticoagulants. In this PCI subgroup, the
primary endpoint of death and non-fatalMI occurred in 10.7%
of patients treated with enoxaparin compared with 13.8% of
patients in theUFH-treated group. There was a non-significant
increase in bleeding in the enoxaparin group: TIMI major
bleeding occurring in 1.6% and 1.4% in the enoxaparin and
UFH arms, respectively. The reduced rate of death or recurrent
MI outweighed the trend towards increased rates in major
bleeding and resulted in a net clinical benefit associated with
enoxaparin compared with UFH.
The only RCT comparing LMWHs with UFH in pPCI is
the ATOLL trial (450 patients randomized to enoxaparin, 460
patients randomized to UFH). Preliminary results of this
previous study, presented at the 2010 European Society of
Cardiology Congress, showed a reduction of the composite
endpoint (death, recurrent MI/ACS or Urgent Revasculariza-
tion) in the enoxaparin arm (6.7% vs. 11.3% in the UFH
group, P = 0.001) without increased bleeding complications.
However, the study was underpowered to assess the effect on
individual outcomes.
The current meta-analysis is the first aimed at assessing the
safety and efficacy of LMWHs vs. UFH in the setting of PCI
(pPCI and after thrombolysis) for STEMI patients.
In our meta-analysis, the benefits in survival associated with
LMWH use were evident in the pPCI group, in whom there
was also a significant decrease in the rates of major bleeding
complications. These data provide further support to the
benefits observed with enoxaparin in the ATOLL trial, the only
RCT available to date in pPCI.
The present results are consistent with those reported in
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Fig. 3. Funnel plot for mortality outcome in the primary percutaneous coronary intervention (pPCI) group. The standard error of each study was plotted
against the log risk ratio for overall mortality. Open circles represent original studies. Solid circles represent hypothetical or imputed studies. Open
diamonds represent the pooled treatment effects from the original studies. The solid diamonds represent the pooled treatment effects incorporating the
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r = 0.72; P = 0.02
Fig. 4. Meta-regression shows survival advantage of low-molecular-
weight heparins (LMWHs) over unfractionated heparin (UFH) therapy as
a function of the UFH event rate (proxy for the risk) in two clinical
scenarios: the thrombolysis in myocardial infarction (TIMI) risk score
(http://www.mdcalc.com/ stemitimiscore) of a 50-year-old hemodynami-
cally stable, male, diabetic patient, with an anterior myocardial infarction
(MI), and time to treatment> 4 h (case A) is 3 (4.4%of risk of mortality),
whereas the TIMI risk score of a 50-year-oldmale with an anteriorMI and
hemodynamic instability (case B) is 4 (7.3% of risk of mortality). Our
meta-regression showed that in case A, the number needed to treat (NNT)
using LMWHs is 62, whereas for the case B it is less than the half of the
case A (NNT = 28). The sizes of the circle are proportional to their
statistical weight in the meta-regression.
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registry involving patients undergoing either elective or
pPCI, where anticoagulation with enoxaparin was associated
with a lower risk of death or MI and a reduced rate of
major bleeding complications as compared with UFH
treatment.
It should be pointed out that some of the studies included in
the current meta-analysis have used different dosing regimens
of LMWHs as well as a different length of LMWH treatment.
Accordingly, a potential explanation for the success of
LMWHs in the setting of pPCI found in our meta-analysis
might be the predominantly intravenous and short LMWH
regimen vs. the predominantly subcutaneous and prolonged
regimen in the lytic studies. However, no single study with its
specific regimen was demonstrated to influence the overall
results for pPCI, as showed in the sensitivity analyses
performed by removing each study and assessing the related
changes in the pooled estimates.
Notably, baseline risk differed across the included studies: in
the ExTRACT-TIMI 25 trial [15], patients underwent PCI
approximately 5 days after thrombolysis for STEMI and were
possibly at a lower risk for periprocedural complications than
in the FINESSE trial [16] where patients underwent PCI
approximately 2 h after presentation and treatment with
thrombolytics.
This finding is supported by our risk profile meta-regression;
the higher the risk, the greater the benefit associated with
LMWH therapy, indicating that the baseline advantage of
LMWHs is increased in more complex patients undergoing
interventions.
Limitations
There are several limitations that must be acknowledged. A
limitation of this meta-analysis, common to all the meta-
analyses based on study-level data, is the lack of individual
patient data that would have further improved the results of the
present study. Pooling data from non-randomized studies
may be subject to confounders. However, observational
data come from the real world and reflect current
practice without selection of populations for randomized
studies which often include patients who are far from
representative of the patients that are actually going to be
treated with the drugs.
On the other hand, some factors may contribute to support
the robustness of our findings, such as the high-quality score of
included studies (Table 2), the stable results in the sensitivity
analyses, in and the absence of heterogeneity among trials.
Some patients in the LMWH group received a mixed
treatment with UFH and LMWHs, as reported in one study
[19], as well as it is not possible to quantify the precise number
of patients undergoing mixed treatment because this informa-
tion was not available in many of the included studies. In the
CLARITY-TIMI 28 different LMWHs were given, even
although enoxaparin was the LMWH most frequently admin-
istered.
Major bleeding
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Fig. 5. Individual and summary relative risks (risk ratios) for major bleeding in patients treated with low-molecular-weight heparins (LMWHs) vs.
unfractionated heparin (UFH).
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Follow-up time was different across the included studies for
the selected endpoints; on the other hand, the longest follow-up
available was chosen and stratified analyses for mortality in the
pPCI groupwere performedwith 1 month or longest follow-up
data, showing consistent benefits in favour of LWMHs.
Patients from the UFH group were more likely to receive
adjunctive antithrombotic medications such as IIb/IIIa
inhibitors. Therefore, it is possible that patients in the UFH
group were at a higher baseline risk, which might have
influenced the interventionalists choice of therapy. On the
other hand, additional meta-regressions, performed using as
covariate the rate of Gp IIb/IIIa inhibitors reported in the
included studies, showed that the use of Gp IIb/IIIa
inhibitors did not influence results on mortality and major
bleeding outcomes. Almost 100% of the patients in the pPCI
group and the vast majority of patients in the PCI after
thrombolysis group were on dual antiplatelet therapy: aspirin
and clopidogrel (300–600 mg as loading dose). Currently,
there are no data regarding the effects of LMWHs vs. UFH
in the pPCI setting with concomitant use of new antiplatelet
agents such as prasugrel or ticagrelor.
Conclusions
This meta-analysis indicates that LMWHs are associated with
a reduction in mortality and major bleeding rates in STEMI
patients treated with pPCI as compared with UFH, and that
patients at the greatest risk derive the maximum benefit.
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